SOLICITATION NOTICE
B -- Human Papillomavirus (HPV) Linear Array Tests
- Notice Date
- 9/8/2003
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-30148-NG
- Response Due
- 9/22/2003
- Archive Date
- 10/7/2003
- Point of Contact
- Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
- E-Mail Address
-
holdcram@exchange.nih.gov, rs442i@nih.gov
- Description
- T The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG) plans to procure on the basis of sole source from Roche Molecular Systems, 1145 Atlantic Avenue, Alameda, California, 94501 Human Papillomavirus (HPV) Linear Array Tests. The services and supplies herein are being procured using the simplified acquisition procedures as stated in FAR Part 13. The North American Industrial Classification System code is 541990 and the business size standard is $6M. A Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED) is being conducted to identify biomarkers that would molecularly distinguish women "at risk" of progressive cervical neoplasia. At present, we are unable to predict with any accuracy, which HPV infections will progress and which will be among the majority that regresses. The purpose of SUCCEED is to therefore identify biomarkers that would distinguish those women who will process to cervical neoplasia from the majority that will not. As part of the enrollment criteria, women will be categorized according to their HPV status. Roche Molecular Systems produces a HPV genotyping assay, the HPV Linear Array Tests, that are crucial to the main objectives for SUCCEED. Women enrolled in SUCCEED will be categorized by their HPV status, which will determine the success of enrollment goals as well as serve as a critical definition for long-term analyses. Roche Molecular system is the only source known to the NCI offering high-throughput HPV testing kits that will allow, by a PCR amplification-based assay), the simultaneous distinction of 37 specific HPV types (including 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 56, 57, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84). This ability is essential to the goals of SUCCEED. The HPV Linear Array Tests are the only array tests known that are proprietary to Roche Molecular Systems. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The capability statement and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can fully meet the requirements. Capability statements must be received in the contracting office by 1:00 PM, EST (local Washington, D.C. time) on September 22, 2003. If you have any questions, please contact Malinda Holdcraft, Purchasing Agent via electronic mail at holdcram@exchange.nih.gov or by fax 301-402-4513. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted.
- Web Link
-
Link to FedBizOpps document.
(http://www.eps.gov/spg/HHS/NIH/RCB/NCI-30148-NG/listing.html)
- Place of Performance
- Address: NCI
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN00429092-F 20030910/030908213115 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |